Avadel Pharmaceuticals (AVDL) announced the publication of combined findings from a social media analysis and a survey of people with narcolepsy taking twice-nightly sodium oxybate. Results showed that these individuals report inconsistent adherence to prescribed dosing, which can lead to negative consequences in their lives. The recommended dosing for twice-nightly sodium oxybates is a first dose at bedtime and a second dose administered 2.5 to 4 hours later. The paper, titled “Understanding the Patient Experience With Twice-Nightly Sodium Oxybate Therapy for Narcolepsy: A Social Listening Experiment,” was published in Brain Sciences.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AVDL:
- Avadel Pharmaceuticals price target lowered to $25 from $27 at H.C. Wainwright
- Avadel Pharmaceuticals Reports Strong Growth with LUMRYZ
- Avadel Pharmaceuticals reports Q3 EPS (3c), consensus (5c)
- AVDL Upcoming Earnings Report: What to Expect?
- Court ruling removes ‘last binary risk’ for Avadel, says H.C. Wainwright
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
